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The aim of this study was to investigate the efficacy and safety of an oral fluoropyrimidine derivative, S-1, in patients with advanced
biliary tract cancer. Patients with pathologically confirmed advanced biliary tract cancer, a measurable lesion, and no history of
radiotherapy or chemotherapy were enrolled. S-1 was administered orally (40mgm
 2 b.i.d.) for 28 days, followed by a 14-day rest
period. A pharmacokinetic study was performed on day 1 in the initial eight patients. In all, 19 consecutive eligible patients were
enrolled in the study between July 2000 and January 2002. The site of the primary tumour was the gallbladder (n¼16), the
extrahepatic bile ducts (n¼2), and the ampulla of Vater (n¼1). A median of two courses of treatment (range, 1–12) was
administered. Four patients achieved a partial response, giving an overall response rate of 21.1%. The median time-to-progression and
median overall survival period were 3.7 and 8.3 months, respectively. Although grade 3 anorexia and fatigue occurred in two patients
each (10.5%), no grade 4 toxicities were observed. The pharmacokinetic parameters after a single oral administration of S-1 were
similar to those of patients with other cancers. S-1 exhibits definite antitumour activity and is well tolerated in patients with advanced
biliary tract cancer.
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The incidence of biliary tract cancer has been steadily increasing in
Japan over the past several decades (Okusaka, 2002). Currently,
biliary tract cancer is the sixth leading cause of death from cancer
in Japan, with statistics from 2002 indicating a total of about 16000
deaths from this disease. As a result of the lack of characteristic
early symptoms, biliary tract cancers are often diagnosed at an
advanced stage, and the prognosis of patients with advanced
biliary tract cancer is dismal. Although systemic treatment is used
for advanced disease, the impact of existing chemotherapy is
virtually negligible. A large number of agents, including 5-
fluorouracil (5-FU), mitomycin-C, and cisplatin, have been tested
as single agents or in combination therapies without appreciable
efficacy (Hejna et al, 1998; van Riel et al, 1999; Yee et al, 2002).
Although recent clinical studies have suggested the potential
activity of gemcitabine for the treatment of biliary tract cancer,
producing response rates of 8 to 36% (Mezger et al, 1998; Raderer
et al, 1999; Gallardo et al, 2001; Gebbia et al, 2001; Kubicka et al,
2001; Penz et al, 2001; Tsavaris et al, 2004), studies on a larger
scale are needed to confirm its efficacy. In any case, to improve the
prognosis of patients with biliary tract cancer, a clear need exists
for new, effective chemotherapeutic agents.
S-1 is a novel orally administered drug that is a combination of
tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and oteracil
potassium (Oxo) in a 1:0.4:1 molar concentration ratio (Shir-
asaka et al, 1996a). 5-chloro-2,4-dihydroxypyridine is a competi-
tive inhibitor of dihydropyrimidine dehydrogenase, which is
involved in the degradation of 5-FU, and acts to maintain
efficacious concentrations of 5-FU in plasma and tumour tissues
(Tatsumi et al, 1987). Oteracil potassium, a competitive inhibitor
of orotate phosphoribosyltransferase, inhibits the phosphorylation
of 5-FU in the gastrointestinal tract, reducing the serious
gastrointestinal toxicity associated with 5-FU (Shirasaka et al,
1993). S-1 therapy in athymic nude rats was associated with the
retention of a higher and more prolonged concentration of 5-FU in
plasma and tumour tissues, when compared with UFT (Shirasaka
et al, 1996b). The antitumour effect of S-1 has been already
demonstrated in a variety of solid tumours: the response rates for
advanced gastric cancer (Sakata et al, 1998; Koizumi et al, 2000),
colorectal cancer (Ohtsu et al, 2000), non-small-cell lung cancer
(Kawahara et al, 2001), and head and neck cancer (Inuyama et al,
2001) in the late phase II studies conducted in Japan were 44–49,
35, 22, and 29%, respectively. In addition, a recent early phase II
study for advanced pancreatic cancer demonstrated a response
rate of 21% in 19 patients (Okada et al, 2002). The efficacy of S-1
for the treatment of gastrointestinal cancer has also been reported
in European patients: the response rates for advanced gastric
cancer (Chollet et al, 2003) and colorectal cancer (Van den Brande
et al, 2003) were 32 and 24%, respectively. However, no previous
reports have described the efficacy and safety of S-1 for the
treatment of biliary tract cancer. Consequently, the present early
phase II study was conducted to evaluate the efficacy and safety of
S-1 in patients with advanced biliary tract cancer.
PATIENTS AND METHODS
Patients
Patients were required to meet the following eligibility criteria:
histologically or cytologically confirmed advanced biliary tract
cancer; at least one measurable lesion; no history of prior
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lantitumour treatment except resection; a Karnofsky performance
status (KPS) of 80–100 points; age of 20–74 years; an estimated
life expectancy of at least 2 months; adequate organ function,
defined as a white blood cell count of 4000–12000mm
 3, a platelet
count X100000mm
 3, a haemoglobin level X10.0g/dl, a normal
serum creatinine level, a serum total bilirubin level p3 times the
upper limit of normal, an aspartate aminotransferase and alanine
aminotransferase level p2.5 times the upper limits of normal; and
written informed consent. Patients who had obstructive jaundice
were considered eligible if their bilirubin level could be reduced to
within 3 times the upper limit of normal after biliary drainage. The
exclusion criteria were as follows: a history of drug hypersensi-
tivity; severe complications, such as infection, heart disease, and
renal disease; symptomatic metastasis of the central nervous
system; active concomitant malignancy; marked pleural effusion or
ascites; watery diarrhoea; and pregnancy or lactation. This study
was approved by the institutional review board at the National
Cancer Center and conducted in accordance with the Good Clinical
Practice guidelines of Japan.
Treatments
S-1 was administered orally at a dose of 40mgm
 2 twice daily after
breakfast and dinner. Three initial doses were established
according to the body surface area (BSA) as follows: BSA
o1.25m
2, 80mgday
 1; 1.25m
2pBSAo1.50m
2, 100mgday
 1;
and 1.50m
2pBSA, 120mgday
 1. S-1 was administered at the
respective dose for 28 days, followed by a 14-day rest period; this
treatment course was repeated until the occurrence of disease
progression, unacceptable toxicities, or the patient’s refusal to
continue. When a grade 3 or greater haematologic or grade 2 or
greater nonhaeamatologic toxicity occurred, the temporary inter-
ruption of the S-1 administrations was allowed until the toxicity
subsided to grade 1 or less. If the daily dose of S-1 was considered
to be intolerable, the retreatment dose was reduced by 20mgday
 1
(minimum dose, 80mgday
 1). If no toxicity occurred, the rest
period shortened to 7 days was allowed. If a rest period of more
than 28 days was required because of toxicity, the patient was
withdrawn from the study. Patients were not allowed to receive
concomitant radiation therapy, chemotherapy, or hormonal
therapy during the study. Patients maintained a daily journal to
record their intake of S-1 and any signs or symptoms that they
experienced. S-1 was provided by Taiho Pharmaceutical Co. Ltd
(Tokyo, Japan).
Response and toxicity evaluation
The response after each course was assessed according to the Japan
Society for Cancer Therapy Criteria (Japan Society for Cancer
Therapy, 1993), which is similar to the World Health Organization
Criteria. Briefly, a complete response (CR) was defined as the
disappearance of all clinical evidence of the tumour for a minimum
of 4 weeks. A partial response (PR) was defined as a 50% or greater
reduction in the sum of the products of two perpendicular
diameters of all measurable lesions for a minimum of 4 weeks. No
change (NC) was defined as a reduction of less than 50% or a less
than 25% increase in the sum of the products of two perpendicular
diameters of all lesions for a minimum of 4 weeks. Progressive
disease (PD) was defined as an increase of 25% or more in the sum
of the products of two perpendicular diameters of all lesions, the
appearance of any new lesion, or a deterioration in the clinical
status that was consistent with disease progression. Primary bile
duct lesions were not considered to be measurable lesions because
the dimensions of such lesions are difficult to measure accurately.
The response duration was calculated from the day of the first
sign of a response until disease progression; time-to-progression
(TTP) was calculated from the date of study entry until
documented disease progression; and overall survival time was
calculated from the date of study entry to the date of death or the
last follow-up. The median probability of the survival period and
the median TTP were estimated using the Kaplan–Meier method.
Compliance was calculated for all treatment courses using the ratio
of the total dose actually administered to the scheduled dose.
Physical examinations, complete blood cell counts, biochemistry
tests, and urinalyses were performed at least biweekly. Adverse
events were evaluated according to the National Cancer Institute
Common Toxicity Criteria, version 2.0. Objective responses and
adverse events were confirmed by an external review committee.
Analysis was to be performed when 19 patients were enrolled. In
this study, the threshold rate was defined as 5% and the expected
rate was set as 15%. If the lower limit of the 90% confidence
interval exceeded the 5% threshold (objective response in four or
more of the 19 patients), S-1 was judged to be effective and we
would proceed to the next large-scale study. If the upper limit of
the 90% confidence interval did not exceed the expected rate of
15% (no objective response in the 19 patients), S-1 was judged to
be ineffective and the study was to be ended. If response was
confirmed in 1–3 of the 19 patients, whether to proceed to the next
study or not was judged based on the safety and survival data from
the present study.
Pharmacokinetics
A pharmacokinetic study was performed in the first eight patients
enrolled in the study. Blood (5ml) was collected before and 1, 2, 4,
6, 8, 10, and 12h after the administration of S-1 on day 1 of the first
course. The plasma was then separated by centrifugation and
stored at  201C until analysis. Plasma concentrations of FT were
quantified using high-performance liquid chromatography with
UV detection, and the concentrations of 5-FU, CDHP, and Oxo
were quantified using gas chromatography-negative ion chemical
ionisation mass spectrometry, as reported previously (Matsushima
et al, 1997).
Pharmacokinetic parameters, including the maximum plasma
concentration (Cmax,n gm l
 1), time to reach Cmax (Tmax, h), area
under the concentration vs time curve for zero to infinity (AUC0–
N,n ghm l
 1), and the elimination half-life (T1/2, h) were calculated
using a noncompartment model and Win-Nonlin software,
Version 3.1 (Pharsight, Apex, NC, USA).
RESULTS
Patients
Nineteen consecutive eligible patients with advanced biliary tract
cancer were enrolled in the study between July 2000 and January
2002 at the National Cancer Center Hospital, Tokyo, Japan. The
patient characteristics are summarised in Table 1. Before the start
of the study, six patients had received surgical resection and seven
patients had undergone percutaneous or endoscopic biliary
drainage for obstructive jaundice. Of the 19 patients, 17 had
metastatic disease at the time of their enrollment in the study,
while two patients were diagnosed as having locally advanced
disease. The liver was the most common site of metastases (14
patients), followed by the distant lymph nodes (11 patients) and
the lungs (three patients).
Treatments
In all, 19 patients were given a total of 63 courses of chemotherapy,
with a median of two courses each (range, 1–12). The initial
administered dose of S-1 was 100mgday
 1 in seven patients and
120mgday
 1 in 12 patients. Dose reduction was required in one
patient because of grade 2 diarrhoea after the third course of
treatment. The reasons for treatment discontinuation were as
follows: disease progression (16 patients), grade 3 diarrhoea and
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lgrade 3 stomatitis (one patient), prolonged grade 2 nausea (one
patient), and patient’s request for transference to another hospital
(one patient). Except for two patients, in whom treatment was
abandoned because of toxicities, all the patients were treated as
outpatients. The overall compliance rate was 94.3%.
Response and survival
Of the 19 patients, none of the patients showed a CR but four
patients achieved a PR, giving an overall response rate of 21.1%
(95% confidence interval, 6.1–45.6%) (Table 2). The median
response duration was 6.7 months (range, 2.8–10.0 months). Nine
patients showed NC and five patients had PD. The tumour
response could not be evaluated in one patient because the patient
was transferred to another hospital, for personal reasons, prior to
the response evaluation. At the time of analysis, 18 of the 19
patients had died because of disease progression. The median TTP
was 3.7 months, and the overall median survival time was 8.3
months, with a 1-year survival rate of 21.1% (Figure 1).
Toxicity
All 19 patients were assessed for toxicities that are listed in Table 3.
Treatment was generally well tolerated throughout the study.
Although haematologic and gastrointestinal toxicities were com-
mon, most of the toxicities were mild and transient. Grade 3
anorexia and fatigue occurred in two patients each (10.5%), and
grade 3 anaemia, neutropenia, stomatitis, nausea, diarrhoea, and
fever occurred in one patient each (5.3%). No signs of cumulative
toxicity were noted. Of the 17 patients who were treated as
outpatients, one patient required hospitalisation because of grade
3 nausea, anorexia, and fatigue during the middle of the first
course of treatment. Although one patient died within 8 weeks of
study enrollment because of rapid disease progression, no
treatment-related deaths were observed.
Pharmacokinetics
Table 4 and Figure 2 show the results of the pharmacokinetic study
for S-1 in the current study. The pharmacokinetic parameters for
S-1 in other cancers, as reported by Hirata et al (1999) are also
shown in Table 4 and Figure 2 for reference. Hirata et al
investigated the pharmacokinetic parameters after the single
administration of S-1 at a dose of 40mgm
 2 in 12 Japanese
patients with gastric, colorectal, and breast cancer. The parameters
of 5-FU in both studies were similar, and no large differences in
the parameters of other compounds, including CDHP, were seen.
DISCUSSION
Although most patients with biliary tract cancer have an
unresectable disease at the time of diagnosis, no standard
chemotherapies have been established for this disease (Hejna
Table 1 Patient characteristics (n¼19)
Characteristics No. of patients (%)
Gender
Male 12 (63.2)
Female 7 (36.8)
Median age (years) (range) 59 (44–71)
Karnofsky performance status, points
100 8 (42.1)
90 10 (52.6)
80 1 (5.3)
Median body surface area (m
2) (range) 1.56 (1.37–1.83)
Median first dose (mgm
 2day
 1)
(range)
72.9 (65.8–78.6)
History of surgical resection 6 (31.6)
Primary tumour site
Gallbladder 16 (84.2)
Extrahepatic bile ducts 2 (10.5)
Ampulla of Vater 1 (5.3)
Median CEA (ngml
 1) (range) 6.8 (1–737)
Median CA 19-9 (Uml
 1) (range) 103 (1–48,160)
Table 2 Response results (n¼19)
Total CR PR NC PD NE Response rate (%)
Overall 19 0 4 9 5 1 21.1
Primary tumour site
Gallbladder 16 0 3 8 4 1 18.8
Extrahepatic bile ducts 2 0 0 1 1 0 0
Ampulla of Vater 1 0 1 0 0 0 100.0
CR¼Complete response; PR¼partial response; NC¼no change; PD¼progressive
disease; NE¼not evaluable.
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Figure 1 Time to progression (A) and overall survival time (B).
Table 3 Treatment-related adverse events (n¼19): worst grade
reported during treatment period
Grade
a
Toxicity 1234G rade 1–4 (%) Grade 3–4 (%)
Haematologic
Leukopenia 5300 42.1 0
Neutropenia 4210 36.8 5.3
Anaemia 3410 42.1 5.3
Thrombocytopenia 2000 10.5 0
Nonhaematologic
Nausea 4210 36.8 5.3
Vomiting 4000 21.1 0
Anorexia 3020 26.3 10.5
Stomatitis 3010 21.1 5.3
Diarrhoea 2210 26.3 5.3
Total bilirubin 1100 10.5 0
A L T 2400 31.6 0
A S T 4200 31.6 0
Fatigue 0020 10.5 10.5
Fever 0010 5 . 3 5 . 3
Rash 1000 5 . 3 0
Pigmentation changes 3000 15.8 0
AST¼aspartate aminotransferase; ALT¼alanine aminotransferase.
aNCI Common
Toxicity Criteria, version 2.0.
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let al, 1998; van Riel et al, 1999; Okusaka, 2002; Yee et al, 2002).
Since biliary tract cancer is an uncommon disease, studies of
chemotherapy for biliary tract cancer are relatively few, and the
number of included patients is generally small. In addition, the
response rates and survival times described in published studies
are difficult to compare because most studies contain patients with
heterogeneous tumour groups, such as intrahepatic or extrahepatic
bile duct cancer and gallbladder cancer. 5-fluorouracil has been the
most commonly studied drug for this disease, although the
antitumour effect of single-agent 5-FU is limited, with a response
rate of less than 20%. Although the combined use of 5-FU with
other agents, such as leucovorin, mitomycin C, or cisplatin, often
produces a response rate of over 20% (Polyzos et al, 1996; Ducreux
et al, 1998; Taı ¨eb et al, 2002), the toxicities also become greater;
whether combination therapies contribute to prolonged survival
remains uncertain. In recent small-scale studies, gemcitabine has
shown relatively good response rates, ranging from 8 to 36%, for
biliary tract cancer (Mezger et al, 1998; Raderer et al, 1999;
Gallardo et al, 2001; Gebbia et al, 2001; Kubicka et al, 2001; Penz
et al, 2001; Tsavaris et al, 2004), but large-scale studies are needed
to confirm its efficacy. Therefore, the development of new effective
chemotherapeutic agents is urgently needed to improve survival in
patients with advanced biliary tract cancers.
A novel orally administered drug, S-1, has been developed based
on the biochemical modulations by CDHP, a dihydropyrimidine
dehydrogenase inhibitor, and Oxo, a protector against 5-FU-
induced gastrointestinal toxicity; S-1 has exhibited significant
antitumour effects on various solid cancers (Sakata et al, 1998;
Koizumi et al, 2000; Ohtsu et al, 2000; Inuyama et al, 2001;
Kawahara et al, 2001; Chollet et al, 2003; Van den Brande et al,
2003). Since the drug is available in oral form, S-1 has a potential
advantage, as far as patient convenience is concerned, especially in
terms of quality-of-life. This consideration is very important for
biliary tract cancer patients because their remaining lifespan is
generally short. Consequently, the efficacy of S-1 for the treatment
of biliary tract cancer was examined.
In the current study, S-1 produced a good response rate of
21.1%, which is superior to those obtained with other single
agents, including 5-FU, mitomycin C, and cisplatin (Table 5),
suggesting an antitumour effect of S-1 on biliary tract cancer. In
this study, patients with gallbladder cancer accounted for three of
the four responders; however, the efficacy of S-1 for each primary
tumour site cannot be accurately assessed because of the small
number of subjects analysed.
Table 4 Pharmacokinetic parameters after single administration of S-1 at
a dose of 40mgm
 2
Compound Parameter
Current study
(n¼8)
Hirata’s study
(n¼12)
FT Cmax (ngml
 1) 1721.67400.4 1971.07269.0
Tmax (h) 3.671.1 2.471.2
AUC (nghml
 1) 24643.077915.0
a 28216.977771.4
b
T1/2 (h) 8.272.0 13.173.1
5-FU Cmax (ngml
 1) 146.9762.1 128.5741.5
Tmax (h) 4.070.0 3.571.7
AUC (nghml
 1) 799.87285.3
a 723.97272.7
c
T1/2 (h) 1.970.3 1.970.4
CDHP Cmax (ngml
 1) 245.3764.9 284.67116.6
Tmax (h) 3.371.0 2.171.2
AUC (nghml
 1) 1472.67381.6
a 1372.27573.7
b
T1/2 (h) 3.270.7 3.070.5
Oxo Cmax (ngml
 1) 55.3748.4 78.0758.2
Tmax (h) 3.371.0 2.371.1
AUC (nghml
 1) 230.67140.2
a 365.77248.6
d
T1/2 (h) 2.870.6 3.071.4
Parameters are represented as mean7s.d.
aAUC0–N.
bAUC0–48.
cAUC0–14.
dAUC0–24.F T¼tegafur; 5-FU¼5-fluorouracil; CDHP¼5-chloro-2,4-dihydroxypyr-
idine; Oxo¼oteracil potassium.
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Hirata's study (n = 12)
Figure 2 Plasma concentration–time profiles of FT (K), 5-FU (’),
CDHP (J), and Oxo (&) after administration of S-1. The values are
expressed as the mean7s.d.
Table 5 Recent studies of single-agent chemotherapy for biliary tract cancer
No. of patients
Author Regimen Total Gallbladder Ca. Response rate (%) MST (months)
Takada et al (1994) 5-FU 18 10 0 NA
Taal et al (1993) Mitomycin C 30 13 10 4.5
Okada et al (1994) Cisplatin 13 6 8 5.5
Jones et al (1996) Paclitaxel 15 4 0 NA
Pazdur et al (1999) Docetaxel 17 0 0 NA
Papakostas et al (2001) Docetaxel 25 16 20 8
Sanz-Altamira et al (2001) Irinotecan 25 10 8 10
Mezger et al (1998) Gemcitabine 13 4 8 NA
Raderer et al (1999) Gemcitabine 19 5 16 6.5
Penz et al (2001) Gemcitabine
a 32 10 22 11.5
Kubicka et al (2001) Gemcitabine 23 0 30 9.3
Gallardo et al (2001) Gemcitabine 26 26 36 7
Gebbia et al (2001) Gemcitabine 18 12 22 8
Tsavaris et al (2004) Gemcitabine 30 14 30 14
Current study S-1 19 16 21 8.3
5-FU: 5-fluorouracil; MST: median survival time; NA: not available.
aBiweekly.
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lSince patients with biliary tract cancer tend to suffer various
tumour-related complications, such as cholangitis and impaired
liver function, enhanced chemotherapy-related toxicities, includ-
ing neutropenic sepsis, are a concern. However, S-1 was well
tolerated in the present study, and no grade 4 toxicities occurred.
Haematological toxicities were acceptable and similar to the results
of clinical studies examining S-1 for the treatment of other cancers
in Japan. Gastrointestinal toxicities were also well tolerated, as in
the other Japanese studies, although strong gastrointestinal
toxicities, particularly severe diarrhoea, have been reported in
Western countries (van Groeningen et al, 2000; Cohen et al, 2002;
Chollet et al, 2003; Van den Brande et al, 2003). The difference in
toxicities between the Japanese and Western studies remains
unexplained, although the conversion of FT to 5-FU seems to occur
more slowly in Japanese patients than in patients from other ethnic
groups (Comets et al, 2003). A pharmacokinetic study suggested
that the pharmacokinetic parameters of S-1 were similar in
patients with biliary tract cancer and in patients with other cancers
in Japan.
Since no serious adverse events occurred in this study, most of
the patients were treated as outpatients, enabling a relatively good
quality-of-life. The S-1 compliance rate of the patients was very
good (94.3%), with only one patient requiring a dose reduction
and only two patients discontinuing S-1 because of toxicity. In
view of the favourable toxicity profile, its evaluation in combina-
tion with other agents might be of particular interest to improve
therapeutic results. Combination therapy with S-1 and cisplatin
has already been conducted for gastric cancer, and an excellent
response rate of 76% was reported in a phase II study (Ohtsu et al,
2001).
In conclusion, the results of this study indicate that S-1 is a safe
and active agent for the treatment of patients with biliary tract
cancer. Further investigations of this agent are warranted in this
population of patients with a poor prognosis.
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